News & Updates

The use of sodium glucose cotransporter-2 (SGLT2) inhibitors nearly halves the risk of all-cause mortality at 3 years in patients with wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) and type 2 diabetes (T2D), findings from an observational study suggest.

Use of opioids results in small reductions in pain among adult patients with an aneurysmal subarachnoid haemorrhage (aSAH)-related headache, and higher doses do not appear to significantly boost its efficacy in relieving pain, according to a study.

The novel neurokinin-1 and -3 receptor antagonist elinzanetant appears to reduce the frequency and severity of vasomotor symptoms (VMS), as well as improve sleep and menopause-related quality of life, as shown in two pivotal phase III trials.